Business
Preliminary Results - October
Preliminary Results - October.
About this update from Genedrive Plc
[{"type":"text","content":"\n RNS Number : 0922F EpiStem Holdings plc 06 October 2008 \n \n\n\n\n\nRNS Press Release\n\nFor release: 6th October 2008\n\nPreliminary Results to the 30th June 2008\n\nEpistem Plc (LSE: EHP), the UK epithelial stem cell company, announced today its preliminary results for the period to the 30 June 2008.\n\nExceptional growth\n\nThe 2007/08 financial year saw Epistem continue to build on last year's outstanding performance. The year's results saw an impressive 52% increase in year-on-year turnover with the Epistem share price showing a 30% premium over last year's AIM admission price. \n\n\nHighlights \n\n· Year-on-year sales up 52%\n· Contract Research Services operating margin over two-fold increase\n· Accelerated development of new therapeutic leads\n· £1.1m equity placing to fund new Biomarker business\n· Initial revenues generated from Biomarker business\n· Strong cash balance with improved trading outlook \nFor further details please contact:\n\n\nMatthew Walls\nChief Executive Officer\nEpistem plc +44 (0)161 606 7263\n\nGareth Price, Simon Brown, Jeff Keating \nLandsbanki Securities (UK) Ltd. +44(0)207 426 9000\n\nMike Wort, Anna Dunphy ...